Andrew Witty, CEO of GlaxoSmithKline
Andrew Witty, CEO of GlaxoSmithKline
Andrew Witty, CEO of GlaxoSmithKline

GSK Q4 sales slip as Advair revenue tumbles

February 04, 2015 10:31 AM